Imagion Biosystems secures US FDA trial clearance

Imagion Biosystems (ASX:IBX) achieved a regulatory milestone following formal Investigational New Drug clearance from the United States Food and Drug Administration.

The FDA has issued a 'Study May Proceed' notice and assigned IND number 165081 for the company’s proprietary MagSense HER2 Imaging Agent.

The authorisation grants Imagion permission to advance into a Phase 1b/2 clinical trial specifically targeting patients diagnosed with HER2+ breast cancer, affirming that the enterprise has comprehensively satisfied all logistical, analytical, quality, and safety prerequisites mandatory for human clinical evaluation.

The extensive IND application incorporated rigorous preclinical datasets, exhaustive manufacturing quality control documentation, and a meticulously detailed clinical trial protocol.

Securing this clearance underscores Imagion’s scientific rigour and robust operational execution in navigating highly complex regulatory frameworks.

The company has already engaged strategic trial partners to orchestrate the study and has initiated site engagement and investigator support programmes.

Clinical site contracting is actively underway alongside the synchronisation of data analysis methodologies to guarantee total compliance with global good clinical practices.

Patient recruitment and enrolments are formally projected to commence during the third quarter of 2026, following the finalisation of institutional ethical reviews and site initiation activities across selected clinical venues.

At the time of reporting, Imagion Biosystems’ share price was $0.020.